fbpx
Free shipping over $75 Start Shopping
Buy More and Save: 10% on $50, 15% on $100, 20% on $150     *Excludes MyBlueprint™ DNA kits.

Management of Cardiovascular Disease

WITH ANKASCIN – CLINICAL RESEARCH

The key findings relevant to the use of Ankascin red yeast rice to manage blood cholesterol came from an experimental study in hamsters.

Unlike other animals commonly used in research, hamsters develop many of the key characteristics of human cardiovascular disease when fed a diet that is high in fats and sugar15.

The positive effects of monascin and ankaflavin in animal models led to human clinical trials to evaluate the ability of these molecules to manage blood cholesterol, blood pressure, and blood sugar.

STUDY


MONASCIN AND ANKAFLAVIN ACT AS NOVEL HYPOLIPIDEMIC AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL-RAISING AGENTS IN RED MOLD DIOSCOREA.

AUTHORS: Tzu-Ming Pan, Chun-Lin Lee, & colleagues

JOURNAL: Journal of Agricultural and Food Chemistry

PUBLICATION YEAR: 2010

DESIGN: Experimental

POPULATION: Hamster model of cardiovascular disease

PROCEDURES: Cardiovascular disease was induced in hamsters by feeding them a high-fat diet. They were then given a diet containing purified monacolin K, monascin or ankaflavin for 8 weeks.

RESULTS: Monascin and ankaflavin reduced LDL cholesterol levels by 34 and 42%, respectively,

a reduction comparable to that seen with monacolin K treatment. Blood levels of fat (triglycerides) decreased by 63% (with monascin) and 58% (with ankaflavin), and by 42% with monacolin K. These effects were associated with reduced plaque buildup in the aorta, which is the major artery delivering blood from the heart.

KEY CONCLUSIONS: Monascin and ankaflavin were comparable to monacolin K at reducing blood cholesterol and cardiovascular disease.


Figure 5. Effects of Monascin and Ankaflavinon LDL cholesterol in hamsters.

 

STUDY


RANDOMIZED, DOUBLE-BLIND CLINICAL STUDY OF THE EFFECTS OF ANKASCIN 568 PLUS ON BLOOD LIPID REGULATION

AUTHORS: Tzu-Ming Pan, Sheng-Fu Liu and colleagues

JOURNAL: Journal of Food and Drug Analysis

PUBLICATION YEAR: 2017

DESIGN: Randomized, double-blind, placebo-controlled clinical trial

POPULATION: 40 participants with borderline high blood cholesterol

DOSE: 110 mg of Ankascin per day

DURATION: 8 weeks, followed by a 4-week washout

EVALUATION: Weeks 0 (baseline), 4, 8 and 12 (follow-up)

RESULTS: There was a 19% reduction in LDL cholesterol in participants receiving Ankascin for 4 weeks, and a

20% reduction after 8 weeks. This reduction disappeared when participants stopped taking Ankascin after 8 weeks. LDL cholesterol in the control group did not change over the study period. There were no reports of liver, kidney or muscle toxicity.

KEY CONCLUSIONS: Ankascin safely and effectively reduces LDL cholesterol within 4 weeks of treatment.


Figure 6. Effect of Ankascin treatment on  blood cholesterol levels.  

STUDY


A RANDOMIZED, DOUBLE-BLIND CLINICAL STUDY TO DETERMINE THE EFFECT OF ANKASCIN 568 PLUS ON BLOOD GLUCOSE REGULATION

AUTHORS: Tzu-Ming Pan, Yin-Ruei Wang and colleagues

JOURNAL: Journal of Food and Drug Analysis

PUBLICATION YEAR: 2016

DESIGN: Randomized, double-blind, placebo-controlled clinical trial

POPULATION: 39 diabetic patients

DOSE: 110 mg of Ankascin per day

DURATION: 12 weeks, followed by a 4-week washout

EVALUATION: Weeks 0 (baseline), 6, 12 and 16 (washout)

RESULTS: In patients receiving Ankascin, fasting blood glucose dropped by 8.5% within 6 weeks of treatment. This reduction increased to 9.3% by the end of the treatment period (12 weeks), but had largely disappeared within 4 weeks of the end of treatment. There were no changes in fasting blood glucose in the control group.

KEY CONCLUSIONS: Six weeks of Ankascin treatment was enough to reduce blood glucose levels in diabetic patients.


 
Figure 7Effect of Ankascin treatment on blood glucose levels.

STUDY


A RANDOMIZED, DOUBLE-BLIND CLINICAL STUDY ON BLOOD PRESSURE REDUCTION AND IMPROVEMENT OF BLOOD LIPID PROFILE WITH TREATMENT OF ANKASCIN 568

AUTHORS: Tzu-Ming Pan, Chien-Li Chen and colleagues

JOURNAL: Chinese Journal of Physiology

PUBLICATION YEAR: 2017

DESIGN: Randomized, double-blind, placebo-controlled clinical trial

POPULATION: 21 patients with hypertension

DOSE: 220 mg of Ankascin per day

DURATION: 8 weeks, followed by a 2-week washout

EVALUATION: Weeks 0 (baseline), 2, 4, 6, 8 and 10 (washout)

RESULTS: Systolic and diastolic blood pressure in the treatment group had dropped by an average of 7.7% after 4 weeks of treatment, and returned to baseline levels within 2 weeks of the end of treatment.

KEY CONCLUSIONS: Ankascin may be effective in managing blood pressure in hypertensive patients.


Figure 8Effect of Ankascin treatment onblood pressure

“SIX WEEKS OF ANKASCIN TREATMENT WAS ENOUGH TO REDUCE BLOOD GLUCOSE LEVELS IN DIABETIC PATIENTS.”

REFERENCE:

15. Dalbøge, L. S., Pedersen, P. J., Hansen, G., Fabricius, K., Hansen, H. B., Jelsing, J. and Vrang, N. (2015). A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating Agents. PLoS ONE 10: e0135634

AOR CA

About The Author

You might also like to read